A Phase 2, Open-label Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Feb 2019
At a glance
- Drugs Nivolumab (Primary) ; Rucaparib (Primary)
- Indications Bladder cancer; Ovarian cancer; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- Sponsors Clovis Oncology
- 07 Feb 2019 Planned initiation date changed from 1 Jan 2019 to 1 Feb 2019.
- 31 Jan 2019 Status changed from planning to not yet recruiting.
- 14 May 2018 New trial record